Dr. Nicolas Bisson holds the Canada Research Chair in Proteomics of Cancer. He is an associate professor in the Department of Molecular Biology, Medical Biochemistry and Pathology of the School of Medicine at Laval University, and a regular researcher at the CHU Research Center of Québec – Laval University. He is also a member of the Laval University Cancer Research Center and the Quebec Network for Research on Protein Function, Engineering, and Applications (PROTEO). Dr. Bisson’s work aims to decipher how cells communicate with each other, and how these signaling mechanisms are deregulated in the development of cancers, particularly in the breast and prostate. In the longer term, the goal of his work is to use entire signaling networks as predictive and therapeutic tools for these cancers, in cases for which conventional strategies fail.

 

Communication between the cells that form the tissues of our body is of paramount importance. This dialogue is required, not only to ensure that all body parts develop normally as a result of conception, but also that they function properly throughout our lives. Deregulation of cells to send, receive or correctly assimilate signals from their environment (or other cells) can lead to diseases such as cancer. The cellular actors who assume these tasks are the proteins. Most proteins do not work alone: ​​they combine in pairs, or in small (complexes) or large groups (networks). Dr. Bisson’s team is particularly interested in a group of proteins, called adapters, whose primary function is to associate with different proteins (and with each other) in order to help the cell integrate signals from outside and respond adequately. More particularly, they study the signals received by a family of receptors called tyrosine kinase. Through their work, they aim to identify which cell proteins associate with adapters to form complexes and networks, as well as the mechanisms used by the cell to regulate this non-random process. In addition, they aim to analyze how the composition of complexes varies when the cell receives different signals through tyrosine kinase receptors. Finally, they want to determine if the large protein networks are modified in breast and prostate cancer cells, identify what these changes are, and figure out how it is possible to return them to a normal state. To achieve these goals, the team uses innovative proteomics tools to separate and quantify proteins, cell imaging to observe them, animal models of breast or prostate cancer, and patient samples. Their work will provide new insights into protein networks that are essential to cell communication and life, and how they can be used as prognostic tools or therapeutic targets for the treatment of breast and prostate cancer.

 

Dr. Bisson’s work is funded by the Canadian Institutes of Health Research, the Natural Sciences and Engineering Research Council of Canada, and the Canada Foundation for Innovation.

 

L'Hôtel-Dieu de Québec
9, rue McMahon
1765
Québec, Québec
Canada G1R 2J6
20 entries « 1 of 4 »

Dionne U, Chartier FJM, Lopez de Los Santos Y, Lavoie N, Bernard DN, Banerjee SL, Otis F, Jacquet K, Tremblay MG, Jain M, Bourassa S, Gish GD, Gagne JP, Poirier GG, Laprise P, Voyer N, Landry CR, Doucet N, Bisson N

Direct Phosphorylation of SRC Homology 3 Domains by Tyrosine Kinase Receptors Disassembles Ligand-Induced Signaling Networks.

Journal Article

Mol Cell, 70 (6), pp. 995-1007.e11, 2018, ISSN: 1097-2765.

Abstract | Links:

Aoidi R, Houde N, Landry-Truchon K, Holter M, Jacquet K, Charron L, Krishnaswami SR, Yu BD, Rauen KA, Bisson N, Newbern J, Charron J

Mek1Y130C mice recapitulate aspects of human cardio-facio-cutaneous syndrome.

Journal Article

Dis Model Mech, 11 (3), 2018, ISSN: 1754-8403.

Abstract | Links:

Banerjee SL, Dionne U, Lambert JP, Bisson N

Targeted proteomics analyses of phosphorylation-dependent signalling networks.

Journal Article

J Proteomics, 2018, ISSN: 1874-3919.

Abstract | Links:

Beigbeder A, Chartier FJM, Bisson N

MPZL1 forms a signalling complex with GRB2 adaptor and PTPN11 phosphatase in HER2-positive breast cancer cells.

Journal Article

Sci Rep, 7 (1), pp. 11514, 2017, ISSN: 2045-2322.

Abstract | Links:

Wills MK, Keyvani Chahi A, Lau HR, Tilak M, Guild B, New LA, Lu P, Jacquet K, Meakin SO, Bisson N, Jones N

Signaling adaptor ShcD suppresses extracellular signal-regulated kinase (Erk) phosphorylation distal to the Ret and Trk neurotrophic receptors.

Journal Article

J Biol Chem, 292 (14), pp. 5748-5759, 2017, ISSN: 0021-9258.

Abstract | Links:

20 entries « 1 of 4 »

Active projects

  • Centre de recherche sur le cancer, Subvention, Institutionnel - BDR, BDR - Centres de recherche reconnus, from 1996-05-01 to 2023-04-30
  • Centre hospitalier universitaire de Québec - CHU de Québec-Université Laval, Subvention, Centre hospitalier universitaire de Québec - Université Laval, Centres de recherche affiliés, from 2017-01-01 to 2099-12-31
  • Chaire de recherche du Canada en Protéomique du Cancer, Subvention, Secrétariat des programmes interorganismes à l’intention des établissements, Chaires de recherche du Canada - Fonctionnement, from 2015-10-01 to 2020-10-01
  • PROTEO, le regroupement québécois de recherche sur la fonction, l'ingénierie et les applications des protéines (PROTEO), Subvention, Fonds de recherche du Québec - Nature et technologies, Regroupements stratégiques, from 2015-04-01 to 2021-03-31
  • Regroupement québécois de recherche sur la fonction, la structure et l'ingénierie des protéines, Subvention, Institutionnel - BDR, BDR - Centres de recherche reconnus, from 2014-05-01 to 2020-04-30
  • Targeted Proteomics Analysis of the Adaptor Protein Grb2 Signaling Network Dynamics in Breast Cancer., Subvention, Instituts de recherche en santé du Canada, Subvention de fonctionnement, from 2013-10-01 to 2018-09-30
  • Understanding the specificity and regulation of NCK adaptor proteins, Subvention, Conseil de recherches en sciences naturelles et génie Canada, Subventions à la découverte SD (individuelles et d'équipe), from 2018-04-01 to 2023-03-31

Recently finished projects

  • Analyse génétique et protéomique de la polarité cellulaire., Subvention, Fonds de recherche du Québec - Nature et technologies, Projet de recherche en équipe, from 2015-04-01 to 2018-03-31
  • Developing a more efficient anti-cancer drug against breast cancer. (fonds 0493), Subvention, Fondation de l'Université Laval, from 2014-11-05 to 2017-04-04
  • Establishment of the Canada Research Chair in Cancer Proteomics, Partenariat, Secrétariat des programmes interorganismes à l’intention des établissements, Fonds des leaders John-R.-Evans - CRC (anciennement : Chaires de recherche du Canada - infrastructure et Fonds des leaders - Volet 2), from 2016-01-01 to 2017-03-31
  • Soutien de la Faculté de médecine aux chercheurs chevronnés, Subvention, Université Laval - Soutien à la recherche, from 2016-07-01 to 2018-06-30
  • Understanding the specificity and regulation of NCK adaptor proteins., Subvention, Conseil de recherches en sciences naturelles et génie Canada, Subventions à la découverte SD (individuelles et d'équipe), from 2012-04-01 to 2018-03-31
Data provided by the Université Laval research projects registery